Douglass Hanly Moir Pathology, Sonic Healthcare, Macquarie Park, Australia.
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Australia.
Int J Surg Pathol. 2023 May;31(3):280-288. doi: 10.1177/10668969221101867. Epub 2022 May 29.
. Epithelioid hemangioma is a benign vascular neoplasm associated with FOS and/or FOSB protein overexpression detected by immunohistochemistry (IHC). . The aim of our study was to determine the co-expression or independent IHC expression of FOS and FOSB in a cohort of epithelioid hemangiomas. We also included two cohorts of other vascular lesions: papillary endothelial hyperplasia and lobular capillary hemangioma / pyogenic granuloma. . We identified 50 cases of epithelioid hemangioma, 84% of which were cutaneous and the remaining involved other anatomic locations. Over two thirds of all cases expressed FOSB (68%; 34/50) while FOS immunoreactivity was identified in 46% of all cases. Co-expression of FOSB and FOS occurred in 37% of cases while 76% of all cases stained for at least one of the antibodies. Fifty-eight percent (n = 14/24) and 33% (8/24) of all cases of papillary endothelial hyperplasia expressed FOS and FOSB, respectively. Thirty-two per cent of lobular capillary hemangiomas (n = 8/25) were positive for either FOS or FOSB. . In summary, we present the largest cohort of epithelioid hemangiomas assessed with both FOS and FOSB and demonstrated that the use of both antibodies increases the detection rate of these proliferations by 10%. Nonetheless, the use of thresholds may not be appropriate, as only a subset of lesional endothelial cells label with FOS/FOSB. Over half of all cases of papillary endothelial hyperplasia and a third of lobular capillary hemangiomas also displayed immunoreactivity with FOS and/or FOSB.
上皮样血管内皮细胞瘤是一种良性血管肿瘤,与免疫组化(IHC)检测到的 FOS 和/或 FOSB 蛋白过表达有关。我们的研究目的是确定上皮样血管内皮细胞瘤中 FOS 和 FOSB 的共表达或独立 IHC 表达。我们还纳入了另外两个血管病变队列:乳头状内皮增生和小叶状毛细血管血管瘤/化脓性肉芽肿。我们确定了 50 例上皮样血管内皮细胞瘤,其中 84%为皮肤病变,其余涉及其他解剖部位。所有病例中有超过三分之二表达 FOSB(68%;34/50),而所有病例中有 46%检测到 FOS 免疫反应性。FOSB 和 FOS 的共表达发生在 37%的病例中,而 76%的病例至少有一种抗体染色阳性。所有乳头状内皮增生病例中,有 58%(n=14/24)和 33%(8/24)分别表达 FOS 和 FOSB。小叶状毛细血管血管瘤中有 32%(n=8/25)为 FOS 或 FOSB 阳性。总之,我们展示了最大的上皮样血管内皮细胞瘤队列,同时评估了 FOS 和 FOSB,并表明使用这两种抗体可将这些增生的检出率提高 10%。然而,使用阈值可能并不合适,因为只有一部分病变内皮细胞用 FOS/FOSB 标记。超过一半的乳头状内皮增生和三分之一的小叶状毛细血管血管瘤也显示出 FOS 和/或 FOSB 的免疫反应性。